Takeda aims to address broader structural barriers that prevent patients in underserved communities from receiving care and treatment they deserve
On World Haemophilia Day, Takeda India, part of Takeda Pharmaceutical Company pledges to stand united to support patients for a better life and brighter future. Takeda is committed to driving awareness and conversations around Haemophilia to ensure an increased number of diagnoses and, thus, timely treatment with quality replacement therapy.
Koki Sato, General Manager, Takeda India, commented, “As a company, we are committed to serving patients suffering from Haemophilia and support them in their journey to ensure an improved quality of life. Together with the haematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalised patient care. With our innovative therapies, awareness drives, and initiatives, we aim to contribute towards building a bleed free India by 2030.”
Through Access to Medicine (AtM) strategy, Takeda aims to address the broader structural barriers that prevent patients in underserved communities from receiving the care and treatment they deserve. In addition to AtM, Takeda India in 2017, launched Purna Samparq, a patient support programme to address the critical unmet needs of haemophiliac patients by offering them counselling, diagnostic, physiotherapy, nursing and education support under the guidance of the consulting physician to improve the quality of life.
Gopal Agrawal, Head Market Access, Patient Advocacy, Patient Services, Takeda India, said “We are committed to addressing the unmet needs of patients wherever they may be, and sustainably strengthening local health systems at every stage of the patient journey. We complement this approach with a commitment towards developing an end-to-end access approach to make our highly-innovative medicines available as soon as practically possible.”